New York State Common Retirement Fund increased its stake in Cambrex Co. (NYSE:CBM) by 44.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 244,725 shares of the biotechnology company’s stock after acquiring an additional 74,951 shares during the period. New York State Common Retirement Fund owned about 0.75% of Cambrex worth $13,460,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CBM. YorkBridge Wealth Partners LLC lifted its stake in shares of Cambrex by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 97 shares during the last quarter. Riverhead Capital Management LLC raised its position in Cambrex by 90.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,264 shares during the last quarter. Advisor Group Inc. raised its position in Cambrex by 29.8% during the 2nd quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 615 shares during the last quarter. Flinton Capital Management LLC raised its position in Cambrex by 90.9% during the 2nd quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Sei Investments Co. raised its position in Cambrex by 3,120.9% during the 3rd quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 4,026 shares during the last quarter.

In other Cambrex news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the transaction, the chief executive officer now owns 87,328 shares of the company’s stock, valued at approximately $4,799,546.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.48% of the company’s stock.

A number of research firms have commented on CBM. ValuEngine lowered Cambrex from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Craig Hallum reaffirmed a “buy” rating and set a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. Finally, BidaskClub lowered Cambrex from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Cambrex presently has a consensus rating of “Hold” and a consensus price target of $62.33.

Cambrex Co. (CBM) opened at $50.45 on Monday. The company has a market capitalization of $1,653.65, a P/E ratio of 15.91, a price-to-earnings-growth ratio of 1.13 and a beta of 2.26. Cambrex Co. has a 52-week low of $42.55 and a 52-week high of $62.95.

Cambrex (NYSE:CBM) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. The business had revenue of $112.60 million during the quarter, compared to analyst estimates of $108.44 million. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. Cambrex’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.47 EPS. equities analysts predict that Cambrex Co. will post 2.97 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “New York State Common Retirement Fund Buys 74,951 Shares of Cambrex Co. (CBM)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/new-york-state-common-retirement-fund-buys-74951-shares-of-cambrex-co-cbm/1770903.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with Analyst Ratings Network's FREE daily email newsletter.